A US 2-pack listed at $608 in 2016; France's official price is about €91. Same epinephrine auto-injector. Four myths about why, honestly sorted.
Structured with AI assistance and strictly fact-checked by our editorial team against primary sources. How we work →
Figures come from the US congressional record, France's ANSM medicines database, Australia's PBS, the UK NHS tariff, a JAMA Network Open value analysis, and company filings. Where a number is a dated peak or a reported figure, we say so — the $608 is a 2016 list price, not a 2026 shelf price.
| Market | Figure | Context | Source |
|---|---|---|---|
| United States | $608 / 2-pack (2016 list peak) | The US list climbed from under $100 (2007) to $608.61 for a two-pack by 2016 — the number that put Mylan's CEO before Congress in September 2016. Average out-of-pocket later fell from about $116 (2016) to $76 (2019) as generics arrived, though roughly 1 in 13 privately insured patients still paid over $200. | US congressional record · JGIM (2019) |
| France | ~€91 official (~65% reimbursed) | France's official listed price is about €91.32, with Social Security reimbursing 65% of it. Same epinephrine auto-injector, one negotiated national price. | ANSM (France medicines database) |
| Australia · UK | ~$32 PBS · NHS charge | Australia lists it around AUD 32 on the PBS — or roughly $7 for concession-card holders — via a specialist or hospital script. In Britain it's the standard NHS prescription charge, or nothing with an exemption. | Australia PBS · NHS Business Services Authority |
| The catch — needle-free ≠ cheaper | neffy $710 / 2 doses | The first needle-free option, a nasal spray called neffy, was FDA-approved in August 2024 — but its maker set the wholesale price at $710 for two doses, roughly in line with brand injectors, not below. State caps ($25–$60) exist in only a handful of states; there is no federal limit. | ARS Pharma SEC/FDA · state statutes |
We compare what the auto-injector costs, not what anyone should take, switch, or stop. Nothing here endorses relying on an expired device. Epinephrine decisions belong with you, your pharmacist, and a licensed prescriber.
The headline number belongs to 2016, the peak of the Mylan pricing story — and honesty means labeling it that way rather than implying it's what you'd pay at a counter today. Since then, an authorized generic and a real generic have pulled average out-of-pocket costs down. What hasn't changed is the structure underneath: a single company set the list price on a life-saving device with no close substitute, and for years that price rose with almost nothing to check it. France pays about €91 for the same auto-injector because it negotiates one national price; the US largely pays list.
Industry pharmacists estimate the epinephrine inside costs well under a dollar, with the auto-injector device adding a few dollars more. That is an honest estimate, not an audited accounting figure — but the direction is clear enough that a JAMA Network Open analysis could estimate the value-based ceiling for a twin-pack at roughly $24–$35. Measured against a ~$715 market price, the same analysis put the cost at about $2.7 million per quality-adjusted life year. The gap between what the device is worth and what it's priced at is the whole story.
Relief came in pieces. Mylan's authorized generic launched at $300 in December 2016; the FDA cleared a truly substitutable generic (Teva) in August 2018; branded share collapsed from about 95% of prescriptions in 2015 to a reported 11% by 2019. But the newest option undercuts the "innovation lowers prices" reflex: neffy, the needle-free nasal spray approved in August 2024, launched at a $710 wholesale price for two doses. Before paying list, the practical moves are knowing the authorized generic exists, checking whether your state caps patient cost (only a handful do, and there is no federal cap), and asking the pharmacist about automatic substitution at the counter.
The US list peaked at $608.61 for a two-pack in 2016. France's official price is about €91.32, with Social Security reimbursing 65% (ANSM). Australia lists it around $32 on the PBS — or roughly $7 for concession-card holders — with a specialist or hospital script. In the UK it's the standard NHS prescription charge, or nothing with an exemption. Same epinephrine, same auto-injector.
Not manufacturing. Industry pharmacists estimate the epinephrine itself costs well under a dollar and the device a few dollars more. The 2007-to-2016 climb from under $100 to $608.61 tracked pricing decisions, not chemistry — Mylan's CEO, Heather Bresch, was called before Congress in September 2016 to explain it, and the company later paid a $465 million settlement to the Department of Justice over Medicaid classification (2017).
A JAMA Network Open analysis estimated the value-based ceiling for an epinephrine twin-pack at roughly $24–$35, assuming it cuts fatality risk tenfold. At the ~$715 market price the researchers used instead, the cost worked out to about $2.7 million per quality-adjusted life year — a gap between what the device is worth and what it's priced at.
Slowly. Mylan launched its own authorized generic at $300 that December, but the FDA didn't approve a true, automatically substitutable generic until August 2018 (Teva). Branded share fell from about 95% of prescriptions (2015) to a reported 11% (2019), and average out-of-pocket spending dropped from about $116 to $76 (2019) — though roughly 1 in 13 privately insured patients still paid over $200.
The first needle-free option, a nasal spray called neffy, was FDA-approved in August 2024 — but its maker set the wholesale price at $710 for two doses, roughly in line with brand injectors, not below. A pediatric version followed in March 2025. Needle-free is a convenience difference here, not a price difference.
Know the authorized generic exists, check your state's cap (Colorado and Illinois reportedly cap patient cost near $60 a two-pack; New Jersey at $25 per 30-day supply — only a handful of states, with no federal limit), and ask your pharmacist about automatic substitution before the counter. A cheaper Adrenaclick-style version uses a different device and generally can't be swapped automatically. This is cost information, not medical advice — never rely on an expired auto-injector, and epinephrine decisions belong with a licensed prescriber.
Wellness Vision does not sell medication, book trips, or take referrals. Every figure above traces to the public sources cited — a congressional hearing record, a government medicines database, a peer-reviewed journal, a regulator, and a company filing. This is a cost comparison, not medical advice: nothing here tells anyone to start, stop, switch, or rely on an expired auto-injector, and an epinephrine device is emergency equipment where the right call is always a licensed prescriber's.
📋 Or get the free Medical Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
